FrancophonIA/ELRC3.0 huggingface dataset:
English: Of the randomised patients, 44.9 % had a complete/partial response and 51.9 % had a response of stable disease to pemetrexed plus cisplatin induction.
Croatian: Od svih randomiziranih bolesnika njih je 44,9% imalo kompletan/djelomičan odgovor na uvodno liječenje pemetreksedom u kombinaciji s cisplatinom, a 51,9% njih odgovor u obliku stabilne bolesti.
English: Always use this medicine exactly as your doctor or pharmacist has told you.
Croatian: Uvijek koristiti ovaj lijek točno onako kako Vam rekao Vaš liječnik .Provjerite sa svojim liječnikom ili ljekarnikom ako niste sigurni.
English: You must continue taking the folic acid for 21 days after the last dose of Pemetrexed Accord.
Croatian: Morate nastaviti koristiti folatnu kiselinu još najmanje 21 dan nakon posljednje doze lijeka Pemetrexed Accord.
English: A white to either light yellow or greenish-yellow lyophilised powder.
Croatian: Bijeli do svijetložuti ili zelenkasto-žuti liofilizirani prašak.
English: The 1 year and 2 year survival rates for patients on pemetrexed were 58 % and 32 % respectively, compared to 45 % and 21 % for patients on placebo.
Croatian: Za bolesnike liječene pemetreksedom stopa jednogodišnjeg preživljenja iznosila je 58%, a stopa dvogodišnjeg preživljenja 32%, u usporedbi s 45% odnosno 21% za bolesnike koji su primali placebo.
English: When using Pemetrexed Accord in combination with cisplatin:
Croatian: Kad se Pemetrexed Accord primjenjuje u kombinaciji s cisplatinom:
English: If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Pemetrexed Accord.
Croatian: Ako ste nedavno cijepljeni, obavijestite o tome svog liječnika jer to može izazvati štetne učinke uz primjenu lijeka Pemetrexed Accord.
English: • Obligation to conduct post-authorisation measures Not applicable
Croatian: • Obaveza provođenja mjera nakon davanja odobrenja
English: Radiation recall (a skin rash like severe sunburn) which can occur on skin that has previously been exposed to radiotherapy, from days to years after the radiation.
Croatian: Radijacijski „recall“ dermatitis (kožni osip poput teške opekline od sunca) koji se može pojaviti na koži prethodno izloženoj zračenju, više dana ili više godina nakon zračenja.
English: How to store Pemetrexed Accord Contents of the pack and other information
Croatian: Kako čuvati lijek Pemetrexed Accord Sadržaj pakiranja i druge informacije
English: The other ingredients are mannitol, hydrochloric acid and sodium hydroxide (see section 2).
Croatian: Drugi sastojci su manitol, kloridna kiselina i natrijev hidroksid (vidjeti dio 2)
English: Gemcitabine/ cisplatin (N= 830)
Croatian: Gemcitabin/ Cisplatin (n = 830)
English: Women of childbearing potential must use effective contraception during treatment with pemetrexed (see section 4.6).
Croatian: Žene generativne dobi moraju koristiti učinkovitu kontracepciju tijekom liječenja pemetreksedom (vidjeti dio 4.6).
English: Patients must take oral folic acid or a multivitamin containing folic acid (350 to 1000 micrograms) on a daily basis.
Croatian: Bolesnici moraju svakodnevno peroralno koristiti folnu kiselinu ili multivitaminski pripravak koji sadrži folnu kiselinu (350 do 1000 mikrograma).
English: For storage conditions after reconstitution of the medicinal product, see section 6.3.
Croatian: Uvjete čuvanja nakon rekonstitucije lijeka, vidjeti u dijelu 6.3.
English: Hydrochloric acid (E507) (for pH adjustment) Sodium hydroxide (E524) (for pH adjustment)
Croatian: 6.1 Popis pomoćnih tvari manitol (E421) kloridna kiselina (E507) (za podešavanje pH vrijednosti) natrijev hidroksid (E524) (za podešavanje pH vrijednosti)
English: Docetaxel N = 276
Croatian: Docetaksel n = 276
English: Progression free survival (months) Median
Croatian: Preživljenje bez progresije bolesti (mjeseci) medijan
English: If you experience sudden breathlessness, intense chest pain or cough with bloody sputum (uncommon)(may indicate a blood clot in the blood vessels of the lungs)
Croatian: ako iskusite iznenadni nedostatak zraka, osjećate intenzivnu bol u prsima ili iskašljavate krv (manje često) (može ukazivati na krvni ugrušak u krvnim žilama u plućima).
English: Dose of Pemetrexed Accord (mg/m2)
Croatian: Doza lijeka Pemetrexed Accord (mg/m2)
English: Pemetrexed Accord should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Croatian: Pemetrexed Accord se mora primjenjivati u obliku intravenske infuzije u trajanju od 10 minuta prvog dana svakog 21-dnevnog ciklusa.
English: The percentage of patients that received post study treatment was 64.3 % for pemetrexed and 71.7 % for placebo.
Croatian: Postotak bolesnika koji su liječeni nakon završetka ispitivanja iznosio je 64,3% u skupini koja je primala pemetreksed te 71,7% u skupini koja je primala placebo.
English: What Pemetrexed Accord contains
Croatian: Što Pemetrexed Accord sadrži
English: The relative treatment effect of pemetrexed was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Croatian: Relativan učinak liječenja pemetreksedom bio je konzistentan u svim podskupinama (uključujući podskupine prema stadiju bolesti, odgovoru na uvodno liječenje, ECOG izvedbeni status, pušački status, spol, histološki tip tumora i dob) te podjednak onome opaženom u nekorigiranim analizama OS-a i PFS-a.
English: Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1000 micrograms) that you must take once a day while you are taking Pemetrexed Accord.
Croatian: Vitaminska nadoknada: liječnik će Vam propisati folatnu kiselinu (vitamin) koja se uzima kroz usta ili multivitaminski pripravak koji sadrži folatnu kiselinu (350 do 1000 mikrograma), koji morate koristiti jedanput na dan za vrijeme liječenja lijekom Pemetrexed Accord.
English: Calculate the dose and the number of Pemetrexed Accord vials needed.
Croatian: Izračunajte dozu i potreban broj bočica lijeka Pemetrexed Accord.
English: Limited clinical data from a separate randomized, Phase 3, controlled trial, suggest that efficacy data (overall survival, progression free survival) for pemetrexed are similar between patients previously pre treated with docetaxel (n = 41) and patients who did not receive previous docetaxel treatment (n = 540).
Croatian: Ograničeni klinički podaci iz zasebnog randomiziranog kontroliranog ispitivanja faze III ukazuju na to da su podaci o djelotvornosti (ukupno preživljenje, preživljenje bez progresije bolesti) za pemetreksed podjednaki u bolesnika prethodno liječenih docetakselom (n = 41) i bolesnika koji prethodno nisu primali docetaksel (nn = 540).
English: This medicine is for single use only.
Croatian: Lijek je isključivo za jednokratnu primjenu.
English: 100 % of previous dose a National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) b Excluding neurotoxicity
Croatian: 100% prethodne doze a Zajednički kriteriji toksičnosti Nacionalnog instituta za rak (CTC v2.0; NCI 1998) b Osim neurotoksičnosti
English: At least five doses of folic acid must be taken during the seven days preceding the first dose of pemetrexed, and dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Croatian: Bolesnici moraju uzeti najmanje pet doza folne kiseline tijekom sedam dana koji prethode prvoj dozi pemetrekseda te je moraju nastaviti koristiti za cijelog trajanja liječenja i još 21 dan nakon posljednje doze pemetrekseda.
English: What Pemetrexed Accord is and what it is used for What you need to know before you use Pemetrexed Accord How to use Pemetrexed Accord Possible side effects
Croatian: Što je Pemetrexed Accord i za što se koristi Što morate znati prije nego počnete koristiti lijek Pemetrexed Accord Kako koristiti Pemetrexed Accord
English: Before the start of any cycle of chemotherapy, patients are required to have the following: absolute neutrophil count (ANC) should be  1500 cells/mm3 and platelets should be  100,000 cells/mm3.
Croatian: Prije početka svakog ciklusa kemoterapije bolesnici moraju imate sljedeće vrijednosti laboratorijskih parametara: apsolutni broj neutrofila (ABN) mora biti ≥ 1500 stanica/mm3, a broj trombocita mora biti ≥ 100 000 stanica/mm3.
English: 5.2 Preclinical safety data
Croatian: 5.3 Neklinički podaci o sigurnosti primjene
English: Concomitant administration of substances that are also tubularly secreted (e.g. probenecid, penicillin) could potentially result in delayed clearance of pemetrexed.
Croatian: Istodobna primjena lijekova koji se također uklanjaju tubularnom sekrecijom (npr. probenecid, penicilin) može rezultirati odgođenim klirensom pemetrekseda.
English: For instructions on reconstitution and dilution of Pemetrexed Accord before administration, see section 6.6.
Croatian: Za upute o rekonstituciji i razrjeđivanju lijeka Pemetrexed Accord prije primjene, vidjeti dio 6.6.
English: Survival Probability
Croatian: Ukupno preživljenje
English: In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and acetylsalicylic acidat higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Croatian: U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen > 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.
English: If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Pemetrexed Accord.
Croatian: Ako ste primali ili ćete primati terapiju zračenjem, obavijestite o tome svog liječnika jer se uz primjenu lijeka Pemetrexed Accord mogu pojaviti rane ili kasne reakcije na zračenje.
English: Pemetrexed*** (N = 800)
Croatian: Pemetreksed*** (N=800)
English: Pemetrexed Accord in combination with cisplatin
Croatian: Pemetrexed Accord u kombinaciji s cisplatinom
English: The median time from the start of pemetrexed plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm.
Croatian: Medijan vremena od početka uvodnog liječenja pemetreksedom i cisplatinom do početka terapije održavanja iznosio je 2,96 mjeseci i u skupini koja je primala pemetreksed i u skupini koja je primala placebo.
English: Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation treatment is frequent.
Croatian: Zbog povećanog rizika od tromboze onkološkim se bolesnicima često daje antikoagulantna terapija.
English: For precautions to be taken before handling or administering Pemetrexed Accord, see section 6.6.
Croatian: Za mjere opreza koje je potrebno poduzeti prije rukovanja ili primjene lijeka Pemetrexed Accord, vidjeti dio 6.6.
English: You must contact your doctor immediately if you notice any of the following: Fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection(since you might have less white blood cells than normal which is very common).
Croatian: vrućicu ili infekciju (često): ako Vam je tjelesna temperatura 38°C ili viša, ako se znojite ili imate neke druge znakove infekcije (jer broj bijelih krvnih stanica može biti niži od normalnog, što je vrlo česta pojava).
English: Rare (may affect up to 1 in 1,000 people)
Croatian: Rijetke (mogu se javiti u do 1 na 1000 bolesnika)
English: - If you have any further questions, ask your doctor , pharmacist or nurse.
Croatian: - Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili medicinskoj sestri.
English: Clinically relevant Grade 3 and Grade 4 laboratory toxicities were similar between integrated Phase 2 results from three single agent pemetrexed studies (n= 164) and the Phase 3 single agent pemetrexed study described above, with the exception of neutropenia (12.8 % versus 5.3 %, respectively) and alanine aminotransferase elevation (15.2 % versus 1.9 %, respectively).
Croatian: Klinički značajni oblici toksičnosti stupnja 3 i 4 utvrđeni laboratorijskim pretragama bili su podjednaki u objedinjenim rezultatima triju ispitivanja faze II pemetrekseda u monoterapiji (n = 164) i rezultatima gore opisanog kliničkog ispitivanja faze III pemetrekseda u monoterapiji, s iznimkom neutropenije (12,8% naspram 5,3%) i povišenih vrijednosti alanin aminotransferaze (15,2% naspram 1,9%).
English: Pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia and anaemia (or pancytopenia) (see section 4.8).
Croatian: Pemetreksed može suprimirati funkciju koštane srži, što se očituje neutropenijom, trombocitopenijom i anemijom (ili pancitopenijom) (vidjeti dio 4.8).
English: Patients with renal impairment: (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method)
Croatian: Bolesnici s oštećenjem bubrega: (serumski klirens izračunat standardnom Cockcroftovom i Gaultovom formulom ili metodom mjerenja brzine glomerularne filtracije Tc99m-DPTA): Pemetreksed se prvenstveno eliminira putem bubrega u nepromijenjenom obliku.
English: Patients must receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving cisplatin (see also cisplatin Summary of Product Characteristics for specific dosing advice).
Croatian: Prije i/ili nakon primjene cisplatina bolesnici moraju primiti odgovarajući antiemetik i primjerenu hidrataciju (vidjeti i posebne preporuke za doziranje u Sažetku opisa svojstava lijeka za cisplatin).
English: Median overall survival in months (95 % CI)
Croatian: Medijan ukupnog preživljenja u mjesecima (95% CI)
English: Very common (may affect more than 1 in 10 people)
Croatian: Vrlo česte (mogu se javiti u više od 1 na 10 bolesnika)
English: Concomitant administration of nephrotoxic drugs (e.g. aminoglycoside, loop diuretics, platinum compounds, cyclosporin) could potentially result in delayed clearance of pemetrexed.
Croatian: Istodobna primjena s nefrotoksičnim lijekovima (npr. aminoglikozidom, diureticima Henleove petlje, spojevima platine, ciklosporinom) može rezultirati odgođenim klirensom pemetrekseda.
English: Pemetrexed Accord must only be administered under the supervision of a physician qualified in the use of anti-cancer chemotherapy.
Croatian: Pemetrexed Accord se smije primjenjivati samo pod nadzorom liječnika koji je obučen za primjenu antitumorske kemoterapije.
English: If patients develop non-haematologic toxicities  Grade 3 (excluding neurotoxicity), Pemetrexed Accord should be withheld until resolution to less than or equal to the patient's pre-therapy value.
Croatian: Razvije li se u bolesnika nehematološka toksičnost stupnja ≥ 3 (osim neurotoksičnosti), primjena lijeka Pemetrexed Accord mora se prekinuti dok se vrijednosti ne vrate na razinu prije liječenja ili nižu.
English: Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji iza oznake Rok valjanosti.
English: Each pack of Pemetrexed Accord consists of one vial.
Croatian: Svako pakiranje lijeka Pemetrexed Accord sadrži jednu bočicu.
English: Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer - ITT population and histology subgroups.
Croatian: Djelotvornost pemetrekseda + cisplatina u odnosu na gemcitabin + cisplatin u prvoj liniji liječenja raka pluća nemalih stanica - ITT populacija i podskupine prema histološkom tipu
English: There is no relevant use of Pemetrexed Accord in the paediatric population in malignant pleural mesothelioma and non-small cell lung cancer.
Croatian: Nema relevantne primjene lijeka Pemetrexed Accord u pedijatrijskoj populaciji za indikaciju malignog pleuralnog mezotelioma i raka pluća nemalih stanica.
English: Pemetrexed + cisplatin Gemcitabine + cisplatin
Croatian: p-vrijednost za superiornost pemetreksed + cisplatin gemcitabin + cisplatin
English: Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to  1500 cells/mm3 and platelet count returns to  100,000 cells/mm3.
Croatian: U bolesnika se tijekom liječenja moraju pratiti pokazatelji mijelosupresije i pemetreksed se ne smije davati sve dok apsolutni broj neutrofila (ABN) ne bude ≥ 1500 stanica/mm3, a broj trombocita  100 000 stanica/mm3.
English: Abbreviations: CI = confidence interval; HR = hazard ratio; ITT = intent to treat; n = total population size.
Croatian: Kratice: CI = interval pouzdanosti; HR = omjer hazarda; ITT = populacija svih uključenih bolesnika; n = ukupan broj bolesnika.
English: Efficacy of pemetrexed vs docetaxel in NSCLC - ITT population Pemetrexed
Croatian: Djelotvornost pemetrekseda u odnosu na docetaksel kod NSCLC - ITT populacija Pemetreksed
English: Table 1 - Dose modification table for Pemetrexed Accord (as single agent or in combination) and cisplatin - Haematologic toxicities Nadir ANC < 500 /mm3 and nadir platelets  50,000 /mm3
Croatian: Tablica 1 - Tablica za prilagodbu doze lijeka Pemetrexed Accord (u monoterapiji ili u kombinaciji) i cisplatina - hematološka toksičnost Najniži ABN < 500 /mm3 i najniži broj trombocita  50 000 /mm3
English: Pemetrexed Accord is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.
Croatian: Pemetrexed Accord se primjenjuje u kombinaciji s cisplatinom, još jednim protutumorskim lijekom, za liječenje zloćudnog pleuralnog mezotelioma, oblika raka koji zahvaća plućne ovojnice, u bolesnika koji prethodno nisu primali kemoterapiju.
English: Progression free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI= 0.94-1.15), and overall response rate was 30.6% (95% CI= 27.3-33.9) for pemetrexed plus cisplatin versus 28.2 % (95% CI= 25.0-31.4) for gemcitabine plus cisplatin.
Croatian: Preživljenje bez progresije bolesti (PFS) i stopa ukupnog odgovora bili su podjednaki između terapijskih skupina: medijan PFS-a iznosio je 4,8 mjeseci za lijek pemetreksed i cisplatin u usporedbi s 5,1 mjeseci za gemcitabin i cisplatin (prilagođen omjer hazarda 1,04; 95% CI = 0,94-1,15), a stopa ukupnog odgovora bila je 30,6% (95% CI = 27,3-33,9) za pemetreksed i cisplatin u usporedbi s 28,2% (95% CI = 25,0-31,4) za gemcitabin i cisplatin.
English: How to use Pemetrexed Accord
Croatian: Kako koristiti Pemetrexed Accord
English: Table 2 - Dose modification table for Pemetrexed Accord (as single agent or in combination) and cisplatin- Non-haematologic toxicities a, b
Croatian: Tablica 2 - Tablica za prilagodbu doze lijeka Pemetrexed Accord (u monoterapiji ili u kombinaciji) i cisplatina - nehematološka toksičnost a,b
English: 50 % of previous dose (both Pemetrexed Accord and cisplatin) a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998)
Croatian: 50% prethodne doze a Zajednički kriteriji toksičnosti Nacionalnog instituta za rak (CTC v2.0; NCI 1998)
English: Reported symptoms of overdose include neutropenia, anaemia, thrombocytopenia, mucositis, sensory polyneuropathy and rash.
Croatian: Prijavljeni simptomi predoziranja uključuju neutropeniju, anemiju, trombocitopeniju, mukozitis, senzornu polineuropatiju i osip.
English: Pemetrexed Accord is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer.
Croatian: Pemetrexed Accord se također primjenjuje u kombinaciji s cisplatinom za početno liječenje bolesnika s uznapredovalim stadijem raka pluća.
English: The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis.
Croatian: Najčešće prijavljene nuspojave povezane s primjenom pemetrekseda, kako u monoterapiji tako i u kombinaciji s drugim lijekovima, su supresija koštane srži, koja se očituje kao anemija, neutropenija, leukopenija ili trombocitopenija; i gastrointestinalna toksičnost, koja se očituje kao anoreksija, mučnina, povraćanje, proljev, konstipacija, faringitis, mukozitis i stomatitis.
English: Pemetrexed Accord is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.
Croatian: Pemetrexed Accord se također primjenjuje u bolesnika s uznapredovalim rakom pluća u kojih je bolest napredovala nakon primjene neke druge početne kemoterapije.
English: Table 3 - Dose modification table for Pemetrexed Accord (as single agent or in combination) and cisplatin - Neurotoxicity
Croatian: Tablica 3 - Tablica za prilagodbu doze lijeka Pemetrexed Accord (u monoterapiji ili u kombinaciji) i cisplatina - neurotoksičnost
English: Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4 % versus 28.9 %, p<0.001), red blood cell transfusions (16.1 % versus 27.3 %, p< 0.001) and platelet transfusions (1.8 % versus 4.5 %, p=0.002).
Croatian: Bolesnici liječeni pemetreksedom i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p < 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p < 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
English: No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified.
Croatian: Bolesnici s oštećenjem jetre: Nije utvrđen odnos između vrijednosti AST-a (SGOT-a), ALT-a (SGPT-a) odnosno ukupnog bilirubina i farmakokinetike pemetrekseda.
English: METHOD AND ROUTE(S) OF ADMINISTRATION For single use only.
Croatian: NAČIN I PUT(EVI) PRIMJENE LIJEKA Samo za jednokratnu primjenu.
English: Patients also required lower administration of erythropoietin/darbopoietin (10.4 % versus 18.1 %, p< 0.001), G-CSF/GM-CSF (3.1 % versus 6.1 %, p=0.004), and iron preparations (4.3 % versus 7.0 %, p=0.021).
Croatian: U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbepoetin (10,4% naspram 18,1%, p<0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p = 0,004) i pripravke željeza (4,3% naspram 7,0%, p = 0,021).
English: Nadir platelets < 50,000 /mm3 with bleedinga, regardless of nadir ANC
Croatian: Najniži broj trombocita < 50 000/mm3 uz krvarenjea, bez obzira na najniži ABN
English: Randomised patients received maintenance treatment until disease progression.
Croatian: Randomizirani bolesnici primali su terapiju odražavanja do progresije bolesti.
English: Colitis (inflammation of the lining of the large bowel, which may be accompanied by intestinal or rectal bleeding)
Croatian: Kolitis (upala sluznice debelog crijeva koja može biti praćena krvarenjem iz crijeva ili završnog dijela debelog crijeva)
English: Chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at 25°C.
Croatian: Dokazano je da su rekonstituirana otopina pemetrekseda i otopina pemetrekseda za infuziju fizikalno i kemijski stabilne tijekom 24 sata ako se čuvaju na 25 °C.
English: Pemetrexed/ cisplatin (N= 839)
Croatian: Pemetreksed/ Cisplatin (n = 839)